Prudential Financial’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
Prudential Financial's RNA Position: Q3 2026 in Review
Prudential Financial opened a new position in Atrium Therapeutics (RNA) in Q3 2026: 46,526 shares worth $385K. The stake represents ﹤0.01% of the portfolio and ranks #2068 among its holdings.
146 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- Prudential Financial held 46,526 shares of Atrium Therapeutics worth $385K as of Q3 2026.
- Atrium Therapeutics was a new Prudential Financial position in Q3 2026.
- Atrium Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q3 2026, its #2068 holding.
- 146 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on Prudential Financial's 13F filing for Q3 2026, filed 16 Nov 2026.